Showing 1 - 5 results of 5 for search 'Zhen-hai Lu', query time: 0.03s Refine Results
  1. 1
    CMTM6 and PD-L1 coexpression is associated with an active immune microenvironment and a favorable prognosis in colorectal cancer

    CMTM6 and PD-L1 coexpression is associated with an active immune microenvironment and a favorable prognosis in colorectal cancer by Ran-Yi Liu, Zhi-Zhong Pan, Xin Yue, Qi-Hua Peng, Chun-Hua Wang, Hong-Min Chen, Rong-Xin Zhang, Zhen-Hai Lu, Gao-Yuan Wang, Wenlin Huang

    Published 2021-02-01
    Get full text
    Article
  2. 2
    Vasorin (VASN) overexpression promotes pulmonary metastasis and resistance to adjuvant chemotherapy in patients with locally advanced rectal cancer

    Vasorin (VASN) overexpression promotes pulmonary metastasis and resistance to adjuvant chemotherapy in patients with locally advanced rectal cancer by Da Kang, Shanshan Huang, Yijun Liao, Siyuan Mi, Jingying Zhou, Yu Feng, Riming Huang, Zhen-hai Lu, Z. Z. Pan, Wenjuan Ma, Gong Chen, Jia-Xing Yue, Jingxiu Huang, R. X. Zhang

    Published 2024-08-01
    Get full text
    Article
  3. 3
    Factors associated with adherence to colonoscopy among individuals who were positive in the preliminary screening for colorectal neoplasms

    Factors associated with adherence to colonoscopy among individuals who were positive in the preliminary screening for colorectal neoplasms by Ji‐Bin Li, Keng‐Jian Ke, Wei‐Li Zhang, Ling‐Yan Wang, Yan‐Ping Wu, Fan Weng, Huan Tian, Zhi‐Yu Qiu, Yin Li, Shi‐Yong Lin, Mei‐Xian Ye, Qing‐Jian Ou, Cheng‐Hua Gong, Zhen‐Hai Lu, Zhi‐Zhong Pan, De‐Sen Wan, Jian‐Hong Peng, Yu‐Jing Fang

    Published 2022-11-01
    Get full text
    Article
  4. 4
    Cetuximab plus FOLFOXIRI versus cetuximab plus FOLFOX as conversion regimen in RAS/BRAF wild-type patients with initially unresectable colorectal liver metastases (TRICE trial): A randomized controlled trial

    Cetuximab plus FOLFOXIRI versus cetuximab plus FOLFOX as conversion regimen in RAS/BRAF wild-type patients with initially unresectable colorectal liver metastases (TRICE trial): A... by De-Shen Wang, Chao Ren, Shan-Shan Li, William Pat Fong, Xiao-Jun Wu, Jian Xiao, Bin-Kui Li, Yun Zheng, Pei-Rong Ding, Gong Chen, Miao-Zhen Qiu, Zhi-Qiang Wang, Feng-Hua Wang, Hui-Yan Luo, Feng Wang, Xiao-Zhong Wang, Ling-Yun Wang, De-Jin Xie, Tao Chen, Li-Ren Li, Zhen-Hai Lu, Xiao-Hui Zhai, Tian-Shu Liu, Ying Yuan, Jia-Qi Chen, Qiong Tan, Zhi-Zhong Pan, De-Sen Wan, Rong Zhang, Yun-Fei Yuan, Rui-Hua Xu, Yu-Hong Li

    Published 2024-05-01
    Get full text
    Article
  5. 5
    Cetuximab plus FOLFOXIRI versus cetuximab plus FOLFOX as conversion regimen in RAS/BRAF wild-type patients with initially unresectable colorectal liver metastases (TRICE trial): A randomized controlled trial.

    Cetuximab plus FOLFOXIRI versus cetuximab plus FOLFOX as conversion regimen in RAS/BRAF wild-type patients with initially unresectable colorectal liver metastases (TRICE trial): A... by De-Shen Wang, Chao Ren, Shan-Shan Li, William Pat Fong, Xiao-Jun Wu, Jian Xiao, Bin-Kui Li, Yun Zheng, Pei-Rong Ding, Gong Chen, Miao-Zhen Qiu, Zhi-Qiang Wang, Feng-Hua Wang, Hui-Yan Luo, Feng Wang, Xiao-Zhong Wang, Ling-Yun Wang, De-Jin Xie, Tao Chen, Li-Ren Li, Zhen-Hai Lu, Xiao-Hui Zhai, Tian-Shu Liu, Ying Yuan, Jia-Qi Chen, Qiong Tan, Zhi-Zhong Pan, De-Sen Wan, Rong Zhang, Yun-Fei Yuan, Rui-Hua Xu, Yu-Hong Li

    Published 2024-05-01
    Get full text
    Article

Search Tools: